• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Does Mild Thrombocytopenia Increase the Risk for Postpartum Hemorrhage After Cesarean Delivery?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • DiSciullo et al. (AJOG Maternal-Fetal Medicine, 2021) assessed whether mild thrombocytopenia is associated with an increased risk of postpartum hemorrhage among women undergoing cesarean delivery

METHODS:

  • Retrospective cohort study
  • Population
    • All women undergoing cesarean delivery at a hospital from September 2015 to June 2018
    • Exclusion: Women with moderate to severe thrombocytopenia or women who required a platelet transfusion
  • Exposure
    • Normal platelet counts (≥150,000/μL)
    • Mild thrombocytopenia (100 to 149,000/μL)
  • Study design
    • Adjusted odds ratios (aOR) were calculated
    • Covariates included in adjustments included: Maternal age | Gestational age | BMI | Scheduled cesarean | Hypertension | Preoperative hemoglobin level
  • Primary outcome
    • PPH (quantitative blood loss ≥1000 mL)
  • Secondary outcomes
    • Frequencies of red blood cell transfusion
    • Wound complications (SSIs, dehiscence, or hematoma)
    • Postpartum Emergency Department (ED) visits

RESULTS:

  • 3133 women
    • Normal platelet levels: 89.3%
    • Mild thrombocytopenia: 9.5%
    • Moderate to severe thrombocytopenia (excluded): 1.3%
  • No differences were seen between normal platelet and mild thrombocytopenia groups for the following
    • Postpartum hemorrhage
      • Normal: 24.6%
      • Mild thrombocytopenia: 25.8%
      • aOR 1.16 (95% CI, 0.88 to 1.54)
    • Need for a red blood cell transfusion
      • Normal: 6.5%
      • Mild thrombocytopenia: 6.7%
      • aOR 1.34 (95% CI, 0.80 to 2.24)
    • Wound complications
      • Normal: 4.5%
      • Mild thrombocytopenia: 5.4%
      • aOR 1.53 (95% CI, 0.88 to 2.64)
    • Postpartum ED visits
      • Normal: 9.0%
      • Mild thrombocytopenia: 10.7%
      • aOR 1.37 (95% CI, 0.92 to 2.03)

CONCLUSION:

  • For women undergoing cesarean delivery, mild thrombocytopenia at the time of delivery did not increase the risk for postpartum hemorrhage, need for transfusions, or wound complications
  • The authors conclude

Our study found no increased risk of PPH or need for red blood cell transfusion in women with mild thrombocytopenia undergoing a cesarean delivery

These negative findings support the exclusion of mild thrombocytopenia as a risk factor for PPH in safety bundle protocols

Learn More – Primary Sources:

Mild gestational thrombocytopenia does not confer increased risk for postpartum hemorrhage or red blood transfusion for women undergoing cesarean delivery

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Thromboelastography (TEG): A Point-Of-Care Tool to Assess Coagulopathy During PPH
Gestational Thrombocytopenia: What is the Threshold for Further Follow-Up?
Mild Thrombocytopenia: Is it a Risk Factor for Postpartum Hemorrhage?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site